Danielle Klump
Family · du Quoin, ILNPI 1972833770
Payments from drug & device makers
Across 134 payments — averaging $16.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$518
- AstraZeneca$472
- Lilly USA, LLC$236
- AbbVie$211
- Bayer$171
- Boehringer Ingelheim$129
- plus $483 from 12 others
What the payments were for
- Food & beverage$2,221100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 34 | $518 |
| AstraZeneca | 28 | $472 |
| Lilly USA, LLC | 12 | $236 |
| AbbVie | 18 | $211 |
| Bayer | 7 | $171 |
| Boehringer Ingelheim | 8 | $129 |
| Dexcom, Inc. | 7 | $119 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $81 |
| Grifols USA, LLC | 3 | $60 |
| Sumitomo Pharma America, Inc. | 2 | $38 |
| Vanda Pharmaceuticals Inc. | 1 | $36 |
| Axsome Therapeutics, Inc. | 1 | $31 |
| Mylan Specialty L.p. | 2 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Pfizer | 1 | $18 |
| Viatris Specialty LLC | 1 | $14 |
How this compares
$2,221 in reported general payments places this provider in the 85th percentile of 4,941 family providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 53 | $47,838 |
| EliquisApixaban | 41 | $36,092 |
| FarxigaDapagliflozin Propanediol | 46 | $34,049 |
| XareltoRivaroxaban | 30 | $20,708 |
| OzempicSemaglutide | 12 | $17,023 |
| RybelsusSemaglutide | 14 | $16,974 |
| MounjaroTirzepatide | 16 | $16,417 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $8,331 |
| LinzessLinaclotide | 11 | $5,766 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $4,703 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $4,219 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $2,998 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 133 | $2,835 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 69 | $2,450 |
| Atorvastatin Calcium | 242 | $1,729 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $129 | $47,83853 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $472 | $42,38159 claims |
| PfizerEliquis | $18 | $36,09241 claims |
| Novo NordiskOzempic, Rybelsus | $518 | $33,99726 claims |
| Lilly USA, LLCMounjaro | $236 | $16,41716 claims |
| AbbVieLinzess, Synthroid | $211 | $6,38739 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,941 family providers in Illinois.
Other family in du Quoin
- Ruth CarricoChicago$582K
- Aleksandra BielawiecBarrington$373K
- Erin SieberNaperville$334K
- Jamie BroganChicago$282K
- Ashley NoethGlen Carbon$271K
- Marita KametasChicago$259K
- Shammona ClarkChicago$247K
- Amanda McKeeMount Vernon$242K
- Brooke KennardBloomington$208K
- Amy BrownellElk Grove Village$202K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.